Silo Pharma signs software deal for 150K shares

The 150,000 shares issued as consideration are restricted until the earliest of 12 months after the effective date, a Change in Control, or Silo's written consent.

Rhea-AI Filing Summary

Silo Pharma, Inc. (SILO) entered into an asset purchase agreement with seller Larry King on October 13, 2026, to acquire certain software and related intellectual property. In consideration, Silo issued King 150,000 shares of common stock.

The shares are subject to a lock-up period beginning on the agreement’s effective date and ending at the earliest of 12 months after that date, a Change in Control, or the company’s written consent. The offer and sale were made in an unregistered transaction in reliance on Section 4(a)(2) of the Securities Act.

Filing Explained

The agreement also requires Larry King to indemnify Silo Pharma for misrepresentations or breaches, infringement of third-party rights by any part of the software, and the seller’s gross negligence, fraud, or intentional misconduct.

8-K Event Classification

3 items: 1.01, 3.02, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Common shares issued as consideration: 150,000 shares Lock-up period: 12 months Common stock par value: $0.0001 per share

3 metrics

Common shares issued as consideration 150,000 shares Issued to Larry King for the purchased assets

Lock-up period 12 months One of the stated conditions for the period to end

Common stock par value $0.0001 per share Common stock issued as consideration

Key Terms

asset purchase agreement, Purchased Assets, Lock Up Period, Section 4(a)(2)

4 terms

asset purchase agreement financial

"entered into an asset purchase agreement"

An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.

Purchased Assets technical

"software and related intellectual property (the “Purchased Assets”)"

Lock Up Period financial

"the “Lock Up Period”"

A lock up period is a set timeframe after a company’s stock becomes publicly tradable during which certain shareholders (often company insiders, early investors, or employees) are contractually barred from selling their shares. It matters to investors because the end of that period can release a large number of shares into the market, like unlocking a storage unit, which can increase supply and potentially push the stock price down or change trading dynamics.

Section 4(a)(2) regulatory

"in reliance upon Section 4(a)(2)"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SILO acquire from Larry King, and what did it issue as consideration?

Silo Pharma agreed to acquire certain software and related intellectual property from Larry King and issued him 150,000 shares of common stock as consideration.

How long are the SILO shares restricted from transfer?

The lock-up period begins on the agreement’s effective date and ends at the earliest of 12 months after that date, a Change in Control, or Silo’s written consent. During the period, the seller may not transfer or dispose of the shares without the company’s prior written consent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 04:30 PM EDT Accepted by SEC EDGAR 10/14/2026 - 04:30 PM EDT Learn about SEC filing dates

false 0001514183 0001514183 2026-10-13 2026-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2026

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-41512		27-3046338
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

677 N. Washington Boulevard Sarasota, FL		34236
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (718) 400-9031

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		SILO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On October 13, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Larry King (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to purchase, certain software and related intellectual property (the “Purchased Assets”).

In consideration for the Purchased Assets, the Company issued to the Seller, 150,000 shares of its common stock, par value $0.0001 per share (the “Shares”). The Shares are subject to a lock-up period beginning on the effective date of the Agreement and ending on the earlier of (i) twelve (12) months after such date, (ii) a Change in Control, as defined in the Agreement, or (iii) written consent of the Company (the “Lock Up Period”). During the Lock Up Period, the Seller may not, without the Company’s prior written consent, directly or indirectly, offer, sell, contract to sell, hedge, pledge, grant any option, right or warrant to purchase, or otherwise transfer or dispose of any of the Shares, or enter into any swap or other agreement or transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of any of the Shares.

The Agreement contains certain representations, warranties and covenants of the parties that are customary for agreements of its type. In addition, the Seller agreed to indemnify the Company for any misrepresentation or breach under the Agreement, infringement of any third-party right by any portion of the software and any acts of gross negligence, fraud or intentional misconduct by the Seller.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 is incorporated herein by reference.

The offer and sale to the Seller of the Shares was made in reliance upon Section 4(a)(2) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1*		Asset Purchase Agreement, dated October 13, 2026, between the Company and Larry King.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILO PHARMA, INC.
Date: October 14, 2026	By:	/s/ Eric Weisblum
		Eric Weisblum
		Chief Executive Officer

2

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 ASSET PURCHASE AGREEMENT, DATED OCTOBER 13, 2026, BETWEEN THE COMPANY AND LARRY 35.1 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB